CJC + IPAMORELIN 10mg

450.00 AED — In stock

CJC‑1295 (No DAC) (Modified GRF 1‑29) is a growth hormone‑releasing hormone (GHRH) analogue engineered to activate the hypothalamic‑pituitary GH axis in a pulsatile fashion. Ipamorelin is a selective ghrelin‑receptor agonist (GHS‑R1a) designed to stimulate growth hormone (GH) release with minimal effects on cortisol or prolactin. When combined, these peptides act through distinct yet complementary pathways to enhance endogenous GH secretion more effectively than either alone. This synergistic peptide stack is studied in research exploring GH modulation, neuroendocrine signaling, tissue biology, body composition, and recovery mechanisms. Key Features 🧬 cGMP manufactured in an FDA‑registered facility📊 ≥98% purity confirmed by HPLC analysis📄 Batch‑specific Certificates of Analysis (COAs) included✒️ Pre‑filled sterile peptide pens for research use only Human-Relevant Research Applications 🔬 Selective GH secretagogue activity - IpamorelinHuman studies demonstrate that Ipamorelin stimulates GH release via the ghrelin receptor with minimal effects on cortisol or prolactin, making it a highly selective secretagogue for research purposes.🔗 https://pubmed.ncbi.nlm.nih.gov/10496658/ 🔬 Synergistic dual-pathway GH modulationMechanistic research shows that combining a GHRH analogue (CJC‑1295 No DAC) with a GHS‑R agonist (Ipamorelin) targets complementary receptors, producing more robust and physiologically pulsatile GH signaling than either agent alone in controlled experimental settings.🔗 https://peptpedia.org/compare/cjc-1295-vs-ipamorelin Key Benefits of CJC‑1295 + Ipamorelin 💥 Enhanced Endogenous GH Release – Dual-pathway stimulation amplifies growth hormone secretion compared with single-agent protocols. 🧪 Synergistic Neuroendocrine Action – Targets both GHRH and ghrelin receptors to explore complementary GH axis regulation. ⚖️ Supports Physiological GH Pulsatility – Mimics natural GH release patterns for more realistic research modeling. 🧬 Versatile Research Applications – Enables investigation into GH-mediated effects on body composition, tissue recovery, metabolism, and anabolic signaling. 🔍 Selective Hormone Modulation – Ipamorelin’s receptor specificity minimizes off-target hormone elevations, improving experimental clarity. Mechanism Summary • CJC‑1295 (No DAC) binds to GHRH receptors on pituitary somatotrophs, stimulating GH synthesis and release through hypothalamic pathways.• Ipamorelin binds selectively to the ghrelin receptor (GHS‑R1a), triggering GH release with minimal impact on cortisol and prolactin.• The combination targets two complementary receptors, providing enhanced pulsatile GH release compared with single-agent use.

More All Products

What is CJC + IPAMORELIN 10mg?

This blend combines two peptides that act on growth hormone release in different ways. CJC-1295 is an analogue of growth hormone-releasing hormone (GHRH), which acts on GHRH receptors in the pituitary gland. Ipamorelin is a five amino acid growth hormone secretagogue that acts on the ghrelin receptor.

The two pathways are thought to work together. GHRH signals set the size of each growth hormone pulse, while ghrelin-receptor signals help trigger it. Combining the two in one product is designed to support the body's own pulsed release of growth hormone.

Also known as: CJC/Ipamorelin, Mod GRF 1-29 and ipamorelin

What are peptides?

What the research covers

Each component has been studied on its own. CJC-1295 has been studied in small human trials, which measured raised growth hormone and IGF-1 levels. Ipamorelin was characterised in laboratory and animal studies as a selective growth hormone secretagogue. Older physiology research suggests that GHRH analogues and ghrelin-receptor agonists can have a combined effect on growth hormone release. We are not aware of published clinical trials of this specific combination. Its long-term effects and safety have not been studied. Neither peptide is approved as a medicine by the US FDA.

References

Formats available

Pen

Pre-filled injection pen for convenient subcutaneous use, prepared by a licensed compounding pharmacy.

Cartridge

Pre-filled cartridge for use with a compatible reusable injection pen.

Vial (injectable)

Lyophilised powder in a sterile vial, reconstituted before subcutaneous injection as directed by your pharmacy.

Storage and handling

Storage: Keep unopened lyophilised vials cool and dry, away from light. After reconstitution, refrigerate at 2-8C, protect from light and do not freeze. Keep pens and cartridges refrigerated at 2-8C and do not freeze. Follow the storage instructions on your pharmacy label.

Peptide Calculator

Specification

Property	Value
Peptide length	Blend of two peptides: CJC-1295 and ipamorelin (5 amino acids)
Formats	Pen, Cartridge, Vial (injectable)

Frequently asked questions

What does the research on this blend show?

Each peptide has been studied separately in small studies. There are no large trials of the combination, so its effects and long-term safety are not well established.

Why combine CJC-1295 and ipamorelin?

They act on two different receptors involved in growth hormone release. The combination is designed to support the natural pulsed pattern. You can also discuss the single peptides with your GP.

Are there side effects with CJC-1295 + Ipamorelin?

Side effects can occur. Your GP will review your health, medication and, where relevant, blood results before prescribing, and you should report anything unexpected.

Which formats are available and how should I store them?

CJC-1295 + Ipamorelin is available as: pen, cartridge, vial (injectable). Your GP will help you choose the most suitable format. Keep unopened lyophilised vials cool and dry, away from light. After reconstitution, refrigerate at 2-8C, protect from light and do not freeze. Keep pens and cartridges refrigerated at 2-8C and do not freeze. Follow the storage instructions on your pharmacy label.

How much CJC-1295 + Ipamorelin should I take?

Your dose is set by our licensed GP following a consultation, and printed on your pharmacy label.